GSK Launches Jemperli and Zejula for Oncology in India

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of GlaxoSmithKline plc, a science-led global healthcare company with a purpose to unite science, technology and talent to get ahead of disease together.

GlaxoSmithKline (GSK) has announced its foray into oncology in India with the launch of Jemperli (dostarlimab) and Zejula (niraparib). Jemperli is the first and only approved PD-1 immunotherapy for second-line treatment of dMMR/MSI-H advanced endometrial cancer in India, while Zejula is the only once-daily oral PARP inhibitor approved in India as first-line monotherapy maintenance for all biomarker types in advanced ovarian cancer.

The launch of these therapies addresses the need for specialized treatments in cancer care, GSK said in a statement. Gynaecological cancers are among the most common cancers in women in India and are on the rise. By 2045, the incidence of endometrial and ovarian cancer in India is projected to increase significantly.

GSK is introducing ‘Phoenix', a Patient Support Program, to allow patients to access these therapies.

Jemperli, a programmed death receptor-1 (PD-1) - blocking antibody, is approved as monotherapy for the treatment of patients with mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer, whose disease has progressed on or after prior platinum-containing chemotherapy.

Zejula is approved as once-daily oral PARP inhibitor approved as monotherapy for first line maintenance treatment for patients with advanced or relapsed epithelial ovarian who are in complete or partial response to platinum-based chemotherapy, regardless of biomarker status.

The molecules launched are supported by robust global clinical evidence and approvals from across 40+ countries including the US, UK and EU. In India, GSK is participating in ongoing oncology clinical trials aimed to extend the indication of dostarlimab to other cancers including non-small cell lung, head and neck and colorectal.